INK PharmaSolutions FZCO™️ and Katalyze AI Announce Strategic Global Partnership
INK PharmaSolutions FZCO™️ and Katalyze AI Announce Strategic Global Partnership
INK PharmaSolutions FZCO™️ and Katalyze AI partner to expand AI solutions for pharma, biotech, and healthcare across North America, the Middle East, and India.
By
Katlyze AI
2
min read
In this News
2
2
min read
Dubai (UAE) and Toronto (Canada), September 25, 2025 – INK PharmaSolutions FZCO™️ (“INK PharmaSolutions™️”) and Katalyze AI today announced a strategic alliance to expand access to advanced AI-driven solutions for pharmaceutical, biotech, and healthcare organizations across North America, the Middle East, and India.
Under this partnership, INK PharmaSolutions FZCO™️, led by Managing Directors Daanyaal Bandukwala and Nicole Serena, will act as Katalyze AI’s distributor and strategic partner across Canada, the United States & Mexico, the Middle East (GCC + broader MENA), and India.
Dubai (UAE) and Toronto (Canada), September 25, 2025 – INK PharmaSolutions FZCO™️ (“INK PharmaSolutions™️”) and Katalyze AI today announced a strategic alliance to expand access to advanced AI-driven solutions for pharmaceutical, biotech, and healthcare organizations across North America, the Middle East, and India.
Under this partnership, INK PharmaSolutions FZCO™️, led by Managing Directors Daanyaal Bandukwala and Nicole Serena, will act as Katalyze AI’s distributor and strategic partner across Canada, the United States & Mexico, the Middle East (GCC + broader MENA), and India.
Dubai (UAE) and Toronto (Canada), September 25, 2025 – INK PharmaSolutions FZCO™️ (“INK PharmaSolutions™️”) and Katalyze AI today announced a strategic alliance to expand access to advanced AI-driven solutions for pharmaceutical, biotech, and healthcare organizations across North America, the Middle East, and India.
Under this partnership, INK PharmaSolutions FZCO™️, led by Managing Directors Daanyaal Bandukwala and Nicole Serena, will act as Katalyze AI’s distributor and strategic partner across Canada, the United States & Mexico, the Middle East (GCC + broader MENA), and India.
Dubai (UAE) and Toronto (Canada), September 25, 2025 – INK PharmaSolutions FZCO™️ (“INK PharmaSolutions™️”) and Katalyze AI today announced a strategic alliance to expand access to advanced AI-driven solutions for pharmaceutical, biotech, and healthcare organizations across North America, the Middle East, and India.
Under this partnership, INK PharmaSolutions FZCO™️, led by Managing Directors Daanyaal Bandukwala and Nicole Serena, will act as Katalyze AI’s distributor and strategic partner across Canada, the United States & Mexico, the Middle East (GCC + broader MENA), and India.
Partnership Benefits
This collaboration brings together Katalyze AI’s proprietary platforms, Digityze AI for document digitization and the Operational Data Platform (ODP) for real-time analytics, with INK PharmaSolutions FZCO™️’s global reach, regional expertise, and deep industry networks.
The partnership is designed to:
Expand presence in highly regulated and strategically important life sciences markets.
Accelerate adoption of AI-driven solutions by leveraging INK PharmaSolutions FZCO™️’s trusted relationships across pharmaceutical companies, biotechnology firms, contract research and development/manufacturing organizations (CRO/CDMOs), and Patient Support Programs (PSPs).
Strengthen market impact by aligning Katalyze AI’s innovation with INK PharmaSolutions FZCO™️’s ability to bridge global markets and support clients in navigating local complexities.
Create shared momentum by combining technological innovation with commercialization expertise, helping both organizations scale globally.
“Our collaboration with Katalyze AI reflects our shared vision to transform life sciences with innovation that is both practical and impactful,” said Daanyaal Bandukwala, Managing Director of INK PharmaSolutions FZCO™️. “INK PharmaSolutions FZCO™️’s ability to connect markets and partners globally will accelerate adoption of AI solutions where they’re needed most.”
Nicole Serena, Managing Director of INK PharmaSolutions FZCO™️, added: “This partnership is about more than distribution…it’s about enabling change. Together, we’re creating pathways for organizations to adopt AI confidently and effectively across regions that demand both innovation and regulatory precision.”
Reza Farahani, CEO of Katalyze AI, commented: “This partnership marks an important step in our mission to make advanced AI accessible to life sciences organizations worldwide. By combining INK PharmaSolutions’ global reach and market expertise with our proprietary AI platforms, we are not only accelerating adoption across highly regulated regions, but also helping manufacturers deliver critical therapies to patients faster, with greater consistency and reliability.”
This collaboration brings together Katalyze AI’s proprietary platforms, Digityze AI for document digitization and the Operational Data Platform (ODP) for real-time analytics, with INK PharmaSolutions FZCO™️’s global reach, regional expertise, and deep industry networks.
The partnership is designed to:
Expand presence in highly regulated and strategically important life sciences markets.
Accelerate adoption of AI-driven solutions by leveraging INK PharmaSolutions FZCO™️’s trusted relationships across pharmaceutical companies, biotechnology firms, contract research and development/manufacturing organizations (CRO/CDMOs), and Patient Support Programs (PSPs).
Strengthen market impact by aligning Katalyze AI’s innovation with INK PharmaSolutions FZCO™️’s ability to bridge global markets and support clients in navigating local complexities.
Create shared momentum by combining technological innovation with commercialization expertise, helping both organizations scale globally.
“Our collaboration with Katalyze AI reflects our shared vision to transform life sciences with innovation that is both practical and impactful,” said Daanyaal Bandukwala, Managing Director of INK PharmaSolutions FZCO™️. “INK PharmaSolutions FZCO™️’s ability to connect markets and partners globally will accelerate adoption of AI solutions where they’re needed most.”
Nicole Serena, Managing Director of INK PharmaSolutions FZCO™️, added: “This partnership is about more than distribution…it’s about enabling change. Together, we’re creating pathways for organizations to adopt AI confidently and effectively across regions that demand both innovation and regulatory precision.”
Reza Farahani, CEO of Katalyze AI, commented: “This partnership marks an important step in our mission to make advanced AI accessible to life sciences organizations worldwide. By combining INK PharmaSolutions’ global reach and market expertise with our proprietary AI platforms, we are not only accelerating adoption across highly regulated regions, but also helping manufacturers deliver critical therapies to patients faster, with greater consistency and reliability.”
This collaboration brings together Katalyze AI’s proprietary platforms, Digityze AI for document digitization and the Operational Data Platform (ODP) for real-time analytics, with INK PharmaSolutions FZCO™️’s global reach, regional expertise, and deep industry networks.
The partnership is designed to:
Expand presence in highly regulated and strategically important life sciences markets.
Accelerate adoption of AI-driven solutions by leveraging INK PharmaSolutions FZCO™️’s trusted relationships across pharmaceutical companies, biotechnology firms, contract research and development/manufacturing organizations (CRO/CDMOs), and Patient Support Programs (PSPs).
Strengthen market impact by aligning Katalyze AI’s innovation with INK PharmaSolutions FZCO™️’s ability to bridge global markets and support clients in navigating local complexities.
Create shared momentum by combining technological innovation with commercialization expertise, helping both organizations scale globally.
“Our collaboration with Katalyze AI reflects our shared vision to transform life sciences with innovation that is both practical and impactful,” said Daanyaal Bandukwala, Managing Director of INK PharmaSolutions FZCO™️. “INK PharmaSolutions FZCO™️’s ability to connect markets and partners globally will accelerate adoption of AI solutions where they’re needed most.”
Nicole Serena, Managing Director of INK PharmaSolutions FZCO™️, added: “This partnership is about more than distribution…it’s about enabling change. Together, we’re creating pathways for organizations to adopt AI confidently and effectively across regions that demand both innovation and regulatory precision.”
Reza Farahani, CEO of Katalyze AI, commented: “This partnership marks an important step in our mission to make advanced AI accessible to life sciences organizations worldwide. By combining INK PharmaSolutions’ global reach and market expertise with our proprietary AI platforms, we are not only accelerating adoption across highly regulated regions, but also helping manufacturers deliver critical therapies to patients faster, with greater consistency and reliability.”
This collaboration brings together Katalyze AI’s proprietary platforms, Digityze AI for document digitization and the Operational Data Platform (ODP) for real-time analytics, with INK PharmaSolutions FZCO™️’s global reach, regional expertise, and deep industry networks.
The partnership is designed to:
Expand presence in highly regulated and strategically important life sciences markets.
Accelerate adoption of AI-driven solutions by leveraging INK PharmaSolutions FZCO™️’s trusted relationships across pharmaceutical companies, biotechnology firms, contract research and development/manufacturing organizations (CRO/CDMOs), and Patient Support Programs (PSPs).
Strengthen market impact by aligning Katalyze AI’s innovation with INK PharmaSolutions FZCO™️’s ability to bridge global markets and support clients in navigating local complexities.
Create shared momentum by combining technological innovation with commercialization expertise, helping both organizations scale globally.
“Our collaboration with Katalyze AI reflects our shared vision to transform life sciences with innovation that is both practical and impactful,” said Daanyaal Bandukwala, Managing Director of INK PharmaSolutions FZCO™️. “INK PharmaSolutions FZCO™️’s ability to connect markets and partners globally will accelerate adoption of AI solutions where they’re needed most.”
Nicole Serena, Managing Director of INK PharmaSolutions FZCO™️, added: “This partnership is about more than distribution…it’s about enabling change. Together, we’re creating pathways for organizations to adopt AI confidently and effectively across regions that demand both innovation and regulatory precision.”
Reza Farahani, CEO of Katalyze AI, commented: “This partnership marks an important step in our mission to make advanced AI accessible to life sciences organizations worldwide. By combining INK PharmaSolutions’ global reach and market expertise with our proprietary AI platforms, we are not only accelerating adoption across highly regulated regions, but also helping manufacturers deliver critical therapies to patients faster, with greater consistency and reliability.”
About INK PharmaSolutions FZCO™️
INK PharmaSolutions FZCO™️ is a global partner to the pharmaceutical, biotech, and healthcare industries. We are dedicated to driving innovation, advancing success, and delivering solutions that shape the future of global healthcare and life sciences.
With expertise spanning consulting, distribution, industry education, and strategic partnerships, INK PharmaSolutions FZCO™️ works across key regions including North America, Europe, the Middle East and North Africa (MENA), India, and beyond. Our integrated approach enables us to bridge markets, connect partners, and support organizations in navigating the complexities of an ever-evolving global landscape.
By combining deep industry knowledge with a commitment to collaboration, we position our clients to stay ahead of change and achieve sustainable impact worldwide.
INK PharmaSolutions FZCO™️ is a global partner to the pharmaceutical, biotech, and healthcare industries. We are dedicated to driving innovation, advancing success, and delivering solutions that shape the future of global healthcare and life sciences.
With expertise spanning consulting, distribution, industry education, and strategic partnerships, INK PharmaSolutions FZCO™️ works across key regions including North America, Europe, the Middle East and North Africa (MENA), India, and beyond. Our integrated approach enables us to bridge markets, connect partners, and support organizations in navigating the complexities of an ever-evolving global landscape.
By combining deep industry knowledge with a commitment to collaboration, we position our clients to stay ahead of change and achieve sustainable impact worldwide.
INK PharmaSolutions FZCO™️ is a global partner to the pharmaceutical, biotech, and healthcare industries. We are dedicated to driving innovation, advancing success, and delivering solutions that shape the future of global healthcare and life sciences.
With expertise spanning consulting, distribution, industry education, and strategic partnerships, INK PharmaSolutions FZCO™️ works across key regions including North America, Europe, the Middle East and North Africa (MENA), India, and beyond. Our integrated approach enables us to bridge markets, connect partners, and support organizations in navigating the complexities of an ever-evolving global landscape.
By combining deep industry knowledge with a commitment to collaboration, we position our clients to stay ahead of change and achieve sustainable impact worldwide.
INK PharmaSolutions FZCO™️ is a global partner to the pharmaceutical, biotech, and healthcare industries. We are dedicated to driving innovation, advancing success, and delivering solutions that shape the future of global healthcare and life sciences.
With expertise spanning consulting, distribution, industry education, and strategic partnerships, INK PharmaSolutions FZCO™️ works across key regions including North America, Europe, the Middle East and North Africa (MENA), India, and beyond. Our integrated approach enables us to bridge markets, connect partners, and support organizations in navigating the complexities of an ever-evolving global landscape.
By combining deep industry knowledge with a commitment to collaboration, we position our clients to stay ahead of change and achieve sustainable impact worldwide.
About Katalyze AI
Katalyze AI is an AI company with proprietary models built specifically for pharmaceutical manufacturing. The compliant, GxP-ready platform structures all manufacturing data (paper-based records, PDFs, spreadsheets) into fully compliant, analytics-ready datasets. This data is then operationalized to optimize production parameters, improve yields, and accelerate decision-making across sites. Capabilities include data digitization, automated drafting of regulated documents, raw material analytics, parametric release, and Agentic AI to streamline complex processes such as root cause analysis and deviation investigations. We work across North America, Europe, and Asia with both large and mid-size clients, including CDMOs and companies producing complex biologics and advanced therapeutics.
Katalyze AI is an AI company with proprietary models built specifically for pharmaceutical manufacturing. The compliant, GxP-ready platform structures all manufacturing data (paper-based records, PDFs, spreadsheets) into fully compliant, analytics-ready datasets. This data is then operationalized to optimize production parameters, improve yields, and accelerate decision-making across sites. Capabilities include data digitization, automated drafting of regulated documents, raw material analytics, parametric release, and Agentic AI to streamline complex processes such as root cause analysis and deviation investigations. We work across North America, Europe, and Asia with both large and mid-size clients, including CDMOs and companies producing complex biologics and advanced therapeutics.
Katalyze AI is an AI company with proprietary models built specifically for pharmaceutical manufacturing. The compliant, GxP-ready platform structures all manufacturing data (paper-based records, PDFs, spreadsheets) into fully compliant, analytics-ready datasets. This data is then operationalized to optimize production parameters, improve yields, and accelerate decision-making across sites. Capabilities include data digitization, automated drafting of regulated documents, raw material analytics, parametric release, and Agentic AI to streamline complex processes such as root cause analysis and deviation investigations. We work across North America, Europe, and Asia with both large and mid-size clients, including CDMOs and companies producing complex biologics and advanced therapeutics.
Katalyze AI is an AI company with proprietary models built specifically for pharmaceutical manufacturing. The compliant, GxP-ready platform structures all manufacturing data (paper-based records, PDFs, spreadsheets) into fully compliant, analytics-ready datasets. This data is then operationalized to optimize production parameters, improve yields, and accelerate decision-making across sites. Capabilities include data digitization, automated drafting of regulated documents, raw material analytics, parametric release, and Agentic AI to streamline complex processes such as root cause analysis and deviation investigations. We work across North America, Europe, and Asia with both large and mid-size clients, including CDMOs and companies producing complex biologics and advanced therapeutics.
Katlyze AI
Katlyze AI
Katlyze AI
Katlyze AI
Katalyze’s AI platform improves yield, traceability, and cycle time across biopharma manufacturing processes. With Katalyze AI, Design, Optimize and Automate Your Bioprocesses at scale.
Katalyze’s AI platform improves yield, traceability, and cycle time across biopharma manufacturing processes. With Katalyze AI, Design, Optimize and Automate Your Bioprocesses at scale.
Katalyze’s AI platform improves yield, traceability, and cycle time across biopharma manufacturing processes. With Katalyze AI, Design, Optimize and Automate Your Bioprocesses at scale.
Katalyze’s AI platform improves yield, traceability, and cycle time across biopharma manufacturing processes. With Katalyze AI, Design, Optimize and Automate Your Bioprocesses at scale.
Katalysts Podcast
Subscribe to Gain Insights About AI Solutions
"With Katalyze AI, we can analyze data in real-time and make informed decisions to optimize our processes." Chris Calabretta
Katalysts Podcast
Subscribe to Gain Insights About AI Solutions
"With Katalyze AI, we can analyze data in real-time and make informed decisions to optimize our processes." Chris Calabretta
Katalysts Podcast
Subscribe to Gain Insights About AI Solutions
"With Katalyze AI, we can analyze data in real-time and make informed decisions to optimize our processes." Chris Calabretta